135 related articles for article (PubMed ID: 21514562)
1. [Management of refractory thyroid cancers].
Schlumberger M
Ann Endocrinol (Paris); 2011 Apr; 72(2):149-57. PubMed ID: 21514562
[TBL] [Abstract][Full Text] [Related]
2. [Angiogenesis and thyroid cancer].
Francis Z; Baudin E; Leboulleux S; Schlumberger M
Presse Med; 2009 Nov; 38(11):1641-6. PubMed ID: 19386465
[TBL] [Abstract][Full Text] [Related]
3. [Refractory thyroid cancers].
Schlumberger M; Chougnet C; Baudin E; Leboulleux S;
Presse Med; 2011 Dec; 40(12 Pt 1):1189-98. PubMed ID: 22078085
[TBL] [Abstract][Full Text] [Related]
4. Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.
Zhang H; Gao B; Shi B
Dis Markers; 2016; 2016():2832980. PubMed ID: 27703281
[No Abstract] [Full Text] [Related]
5. Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.
Isham CR; Netzel BC; Bossou AR; Milosevic D; Cradic KW; Grebe SK; Bible KC
J Clin Endocrinol Metab; 2014 Jun; 99(6):E936-43. PubMed ID: 24628546
[TBL] [Abstract][Full Text] [Related]
6. [Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies].
Malouf G; Baudin E; Soria JC; Schlumberger M
Bull Cancer; 2009 Jan; 96(1):95-101. PubMed ID: 19211364
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib Active in Iodine-Refractory Thyroid Cancer.
Cancer Discov; 2016 Oct; 6(10):OF4. PubMed ID: 27554612
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib improves survival in refractory thyroid cancer.
Mayor S
Lancet Oncol; 2015 Mar; 16(3):e110. PubMed ID: 25683848
[No Abstract] [Full Text] [Related]
9. New therapies for dedifferentiated papillary thyroid cancer.
Fallahi P; Mazzi V; Vita R; Ferrari SM; Materazzi G; Galleri D; Benvenga S; Miccoli P; Antonelli A
Int J Mol Sci; 2015 Mar; 16(3):6153-82. PubMed ID: 25789503
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives.
Scott E; Learoyd D; Clifton-Bligh RJ
Future Oncol; 2016 Nov; 12(22):2603-2613. PubMed ID: 27387641
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
13. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract][Full Text] [Related]
15. [Tyrosine kinase inhibitors for the treatment of papillary thyroid cancer].
Politti U
Clin Ter; 2014; 165(6):e452-63. PubMed ID: 25524205
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
Dadu R; Shah K; Busaidy NL; Waguespack SG; Habra MA; Ying AK; Hu MI; Bassett R; Jimenez C; Sherman SI; Cabanillas ME
J Clin Endocrinol Metab; 2015 Jan; 100(1):E77-81. PubMed ID: 25353071
[TBL] [Abstract][Full Text] [Related]
17. VEGF Trapon inhibits tumor growth in papillary thyroid carcinoma.
Peng XG; Chen ZF; Zhang KJ; Wang PG; Liu ZM; Chen ZJ; Hou GY; Niu M
Eur Rev Med Pharmacol Sci; 2015; 19(2):235-40. PubMed ID: 25683936
[TBL] [Abstract][Full Text] [Related]
18. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
Bible KC; Ryder M
Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeted therapies for patients with refractory thyroid cancer.
Chougnet C; Brassard M; Leboulleux S; Baudin E; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):448-55. PubMed ID: 20554167
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer.
Ho AL; Sherman E
Clin Adv Hematol Oncol; 2011 Jan; 9(1):32-41. PubMed ID: 21326144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
